Trial Profile
Optimizing Vaccine Responsiveness in HIV-1 and HCV Infections by Identifying Determinants of Responsiveness: A Pilot Study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Diphtheria-tetanus vaccine (Primary) ; Hepatitis A-hepatitis B vaccine (Primary)
- Indications Diphtheria; Hepatitis A; Hepatitis B; Tetanus
- Focus Pharmacodynamics; Registrational
- 10 Apr 2012 Additional trial identifier (A5232) identified as reported by ClinicalTrials.gov.
- 29 Mar 2012 Actual end date changed from Sep 2009 to Jul 2009 as reported by ClinicalTrials.gov.
- 13 Feb 2012 Actual patient number is 29 according to ClinicalTrials.gov.